Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijph.IJPH_456_20 http://scihub22266oqcxt.onion/10.4103/ijph.IJPH_456_20 32496239!�!32496239 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32496239&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32496239.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Indian+J+Public+Health 2020 ; 64 (Supplement): S112-S116 Nephropedia Template TP {{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19 |pdf=|usr=}}{{32496239}} gab.com Text Potential pharmacological agents for COVID-19 JO: Indian J Public Health http://www.kidney.de/pget.php?&tw=1&pmid=32496239 #FOAvip A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal. Twit Text FOAVip Potential pharmacological agents for COVID-19 ????Indian J Public Health http://www.kidney.de/pget.php?&tw=1&pmid=32496239 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32496239 #FOAvip English Wikipedia <ref>{{Cite pmid|32496239}}</ref> Potential pharmacological agents for COVID-19 #MMPMID32496239 Kotwani A; Gandra S Indian J Public Health 2020[Jun]; 64 (Supplement): S112-S116 PMID32496239show ga A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal. |Antimalarials/therapeutic use[MESH] |Antiviral Agents/adverse effects/pharmacology/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Clinical Trials as Topic[MESH] |Coronavirus[MESH] |Coronavirus Infections/*drug therapy/therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Immunoglobulins/therapeutic use[MESH] |Interleukins/antagonists & inhibitors[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/therapy[MESH]Potential pharmacological agents for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing